

the substitute Sequence Listing and a computer readable form of the sequence listing (diskette) as required, and a Request for a One Month Extension of Time with the required small entity fee of \$55.00. Please note that Applicant claims small entity status. In addition, to place the application in compliance with the requirements of 37 CFR 1.821 through 1.825, please amend the specification and claims as follows:

IN THE SPECIFICATION:

✓
Page 46, line 11, at the end of the line insert --(SEQ ID NO: 23)--.

✓
Page 46, line 14, at the end of the line, insert --(SEQ ID NO: 24)--.

✓
Page 47, line 13, at the end of the line insert --(SEQ ID NO:25)--.

✓
Page 59, line 14, at the end of the line insert --(SEQ ID NO:26)--.

✓
Page 58, line 15, at the end of the line insert --(SEQ ID NO:27)--.

✓
Page 58, line 16, at the end of the line insert --(SEQ ID NO:28)--.

RECEIVED

JAN 12 2001

TECH CENTER 1600/2000

IN THE CLAIMS:

34. (**Amended**) The method of claim 33, wherein the antisense oligonucleotide is selected from the group consisting of:

5'-GTCCTGGCGCCGCGCCGCGCGTCGCC (SEQ ID NO: 26);

5'-TTCCGATGACCGGCCTTTCGCGGTGA (SEQ ID NO: 27);

and

5'-GTGCACGGAAAGGTGCAGGCCACACT (SEQ ID NO: 28).
